Breaking Pete Crow-Armstrong Makes MLB History in Cubs’ Walk-Off Win Against White Sox China Highlights Robotics Prowess Amidst Global Security Scrutiny Justice Department Defends Prosecution of James Comey Over Social Media Post Tropic Air Helicopter Crashes in Northern Kenya UAE Suspends Trade With Iran Following Missile Fire Report
Wednesday August 19, 2026
76° Honolulu, HI Isolated Rain Showers
Become a Contributor
Section

Business

858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer
Press Release

858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer

858 Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETX-19477, the company’s internally discovered PARG…

Business Wire · 1 minute ago
Read Full Story